Medicine firm's share offer

Hua Han Bio-Pharmaceutical Holdings aims to raise HK$115 million after expenses in an initial public offering on the main board of Hong Kong's stock market to fund product research and development and marketing. The company produces Chinese and Western medicines. It will sell 140.04 million new shares and 15.56 million existing shares at HK$1 each, or at a price-earning ratio of 8.2 times on a pro forma diluted basis.